+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Plasminogen Activator Inhibitor 1 - Drugs In Development, 2021

  • ID: 5402580
  • Report
  • July 2021
  • Region: Global
  • 74 Pages
  • Global Markets Direct
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Plasminogen activator inhibitor-1 (PAI-1) also known as endothelial plasminogen activator inhibitor or is a protein that encodes by the SERPINE1 gene. Elevated PAI-1 is a risk factor for thrombosis and atherosclerosis. PAI-1 is mainly produced by the endothelium and also by other tissue types, such as adipose tissue. PAI-1 inhibits the serine proteases tPA and urokinase and hence inhibit the physiological process that degrades blood clots. PAI-1 inhibits the activity of matrix metalloproteinases (important role in invasion of malignant cells across the basal lamina).

Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) pipeline Target constitutes close to 13 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II and Preclinical stages are 2 and 3 respectively. Similarly, the universities portfolio in Phase II and Preclinical stages comprises 1 and 7 molecules, respectively. Report covers products from therapy areas Cardiovascular, Oncology, Gastrointestinal, Genito Urinary System And Sex Hormones, Respiratory, Central Nervous System, Immunology, Infectious Disease, Genetic Disorders, Hematological Disorders, Metabolic Disorders, Musculoskeletal Disorders and Undisclosed which include indications Arterial Thrombosis, Coronavirus Disease 2019 (COVID-19) Pneumonia, Idiopathic Pulmonary Fibrosis, Non Alcoholic Fatty Liver Disease (NAFLD), Renal Failure, Thrombosis, Acute Respiratory Distress Syndrome, Alpha-1 Antitrypsin Deficiency (A1AD), Beta Thalassaemia, Breast Cancer, Bronchiectasis, Central Nervous System (CNS) Tumor, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colorectal Cancer, Coronavirus Disease 2019 (COVID-19), Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome, Emphysema, Fibrosis, Focal Segmental Glomerulosclerosis (FSGS), Glioblastoma Multiforme (GBM), Graft Versus Host Disease (GVHD), Head And Neck Cancer, Hepatocellular Carcinoma, Inflammatory Bowel Disease, Interstitial Lung Fibrosis, Melanoma, Metastatic Lung Cancer, Mucocutaneous Lymph Node Syndrome (Kawasaki Disease), Multiple Sclerosis, Neuromyelitis Optica (Devic’s Syndrome), Non-Small Cell Lung Carcinoma, Obesity, Pediatric Diffuse Intrinsic Pontine Glioma, Recurrent Glioblastoma Multiforme (GBM), Sickle Cell Disease, Solid Tumor, Stroke, Systemic Sclerosis (Scleroderma), Thromboembolism, Unspecified and Venous (Vein) Thrombosis.

The latest report Plasminogen Activator Inhibitor 1 - Drugs In Development, 2021, outlays comprehensive information on the Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope


  • The report provides a snapshot of the global therapeutic landscape for Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1)
  • The report reviews Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) targeted therapeutics

Reasons to Buy


  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1)Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Introduction
Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Overview
  • Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Companies Involved in Therapeutics Development
  • Accendatech Co Ltd
  • Astellas Pharma Inc
  • Beam Therapeutics Inc
  • Jazz Pharmaceuticals Plc
  • MDI Therapeutics Inc
Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Drug Profiles
  • ACT-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AS-3288802 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Bi-specific Antibody to Inhibit TAFI and PAI-1 for Thrombosis and Stroke - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • defibrotide sodium - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy to Activate SERPINA1 for Alpha-1 Antitrypsin Deficiency - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MDI-2268 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MDI-2517 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Peptide to Inhibit PAI-1 for Arterial Thrombosis and Pulmonary Thromboembolism - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SK-216 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TM-5275 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TM-5441 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TM-5484 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TM-5614 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Dormant Products
Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Discontinued ProductsPlasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) - Product Development Milestones
Featured News & Press Releases
  • May 20, 2021: Jazz to present new data on Defitelio at EHA2021
  • Nov 13, 2020: Beam Therapeutics presents first data highlighting Base Editing Program for Alpha-1 Antitrypsin Deficiency at AASLD
  • Jul 31, 2020: Clinigen receives regulatory approval for Defitelio (Defibrotide) in Australia
  • May 14, 2020: Jazz Pharmaceuticals announces presentation on Defitelio at Virtual EHA 2020 Meeting
  • Apr 29, 2020: Jazz Pharmaceuticals stops enrollment in phase 3 study evaluating Defibrotide for the prevention of Veno-Occlusive Disease
  • Apr 28, 2020: Beam Therapeutics to present first data highlighting base editing program for alpha-1 antitrypsin deficiency at 23rd ASGCT Annual Meeting
  • Nov 07, 2019: Jazz Pharmaceuticals to present abstracts on Defitelio (defibrotide sodium) at ASH 2019 Annual Meeting
  • Oct 10, 2019: Jazz Pharmaceuticals announces first patient enrolled in phase 2 clinical trial evaluating defibrotide for the prevention of CAR-T Associated Neurotoxicity
  • Sep 04, 2019: Launch of Defitelio injection 200mg for the treatment of sinusoidal obstruction syndrome (hepatic veno-occlusive disease)
  • Jun 18, 2019: Marketing approval of Defitelio by MHLW for the treatment of sinusoidal obstruction syndrome / hepatic veno-occlusive disease
  • May 16, 2019: Jazz Pharmaceuticals to present new data on defitelio at upcoming EHA Congress
  • Mar 25, 2019: Experimental drug reverses high cholesterol, obesity-related nonalcoholic fatty liver disease in animals
  • Nov 28, 2018: Jazz Pharmaceuticals to present data on Defitelio at ASH 2018 Annual Meeting
  • Oct 17, 2018: New Drug Application Filed for defibrotide sodium
  • Sep 19, 2018: Nippon Shinyaku announces orphan drug designation granted to NS-73
Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact the Publisher
  • Disclaimer

List of Tables
  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Indications, 2021
  • Number of Products under Development by Companies, 2021
  • Products under Development by Companies, 2021
  • Number of Products under Investigation by Universities/Institutes, 2021
  • Products under Investigation by Universities/Institutes, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Pipeline by Accendatech Co Ltd, 2021
  • Pipeline by Astellas Pharma Inc, 2021
  • Pipeline by Beam Therapeutics Inc, 2021
  • Pipeline by Jazz Pharmaceuticals Plc, 2021
  • Pipeline by MDI Therapeutics Inc, 2021
  • Dormant Products, 2021
  • Discontinued Products, 2021

List of Figures
  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Top 10 Indications, 2021
  • Number of Products by Mechanism of Actions, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Accendatech Co Ltd
  • Astellas Pharma Inc
  • Beam Therapeutics Inc
  • Jazz Pharmaceuticals Plc
  • MDI Therapeutics Inc